Effect of HIV Infection and Menopause Status on Raltegravir Pharmacokinetics in the Blood and Genital Tract

Background This study describes first dose and steady state pharmacokinetics of raltegravir (RAL) in cervicovaginal fluid (CVF) and blood plasma (BP). Methods Three cohorts of women were enrolled sequentially in a single-site, open-label pharmacokinetic study of oral raltegravir 400 mg twice daily: HIV-negative premenopausal, HIV-infected premenopausal and HIV-infected post-menopausal women. BP and CVF were collected over 12 h after a single observed dose and at steady state. RAL concentrations were measured by HPLC-MS methods. Data are expressed as median (IQR). The ANOVA rank-sum test was used to evaluate between-group differences in steady state raltegravir exposure (area under the concentration-time curve over the 12-h dosing interval [AUC0–12 h]). Results First dose pharmacokinetics were obtained in HIV-negative premenopausal women and HIV-infected post-menopausal women only. The median (IQR) BP AUC0–12 h was 3,099 (985–5,959) and 4,239 (2,781–13,695) ng•h/ml and the median (IQR) CVF AUC0–12 h was 1,720 (305–5,288) and 13,797 (11,066–19,563) ng•h/ml for HIV-negative pre-menopausal and HIV-infected post-menopausal women, respectively. All cohorts contributed to steady-state pharmacokinetic profiles. Median (IQR) BP AUC0–12 h did not differ between the groups: 8,436 (3,080–10,111), 5,761 (1,801–10,095) and 6,180 (5,295–8,282) ng•h/ml in HIV-negative premenopausal, HIV-infected premenopausal and HIV-infected post-menopausal women, respectively. There was a trend for lower CVF AUC0–12 h among HIV-negative women 3,164 (1,156–9,540) compared to 11,465 (9,725– 17,138) and 9,568 (4,271–24,306) ng•h/ml HIV-infected premenopausal and HIV-infected post-menopausal women, respectively, but this was not statistically significant (P=0.08). HIV-negative premenopausal women had a median (IQR) CVF:BP AUC0–12 h ratio of 0.46 (0.2–1.1), whereas HIV-infected premenopausal and post-menopausal women had median (IQR) CVF:BP AUC0–12 h ratio of 3.9 (1.2–6.7) and 1.4 (0.7–4.3), respectively. Conclusions This is the first study to investigate RAL exposure in BP and CVF in premenopausal HIV-negative and pre- and post-menopausal HIV-infected women. These data indicate HIV and menopausal status may influence antiretroviral distribution into the female genital tract.

[1]  F. Aweeka,et al.  Raltegravir Pharmacokinetics During Pregnancy , 2014, Journal of acquired immune deficiency syndromes.

[2]  M. Baes,et al.  Vaginal expression of efflux transporters and the potential impact on the disposition of microbicides in vitro and in rabbits. , 2014, Molecular pharmaceutics.

[3]  M. Sobieszczyk,et al.  A forgotten population: older adults with newly diagnosed HIV. , 2014, AIDS patient care and STDs.

[4]  D. Kroetz,et al.  Expression of six drug transporters in vaginal, cervical, and colorectal tissues: Implications for drug disposition in HIV prevention , 2014, Journal of clinical pharmacology.

[5]  J. Lifson,et al.  Persistence of Viral Reservoirs in Multiple Tissues after Antiretroviral Therapy Suppression in a Macaque RT-SHIV Model , 2013, PloS one.

[6]  A. Kashuba,et al.  Single and Multiple Dose Pharmacokinetics of Dolutegravir in the Genital Tract of HIV-Negative Women , 2013, Antiviral therapy.

[7]  S. Poloyac,et al.  Short communication: expression of transporters and metabolizing enzymes in the female lower genital tract: implications for microbicide research. , 2013, AIDS research and human retroviruses.

[8]  H. Jono,et al.  Role of P-glycoprotein in the efflux of raltegravir from human intestinal cells and CD4+ T-cells as an interaction target for anti-HIV agents. , 2013, Biochemical and biophysical research communications.

[9]  N. Shaheen,et al.  Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure , 2013, AIDS.

[10]  M. Hudgens,et al.  Raltegravir Pharmacokinetics in Treatment-Naive Patients Is Not Influenced by Race: Results from the Raltegravir Early Therapy in African-Americans Living with HIV (REAL) Study , 2012, Antimicrobial Agents and Chemotherapy.

[11]  K. Mayer,et al.  Highly active antiretroviral therapy does not completely suppress HIV in semen of sexually active HIV-infected men who have sex with men , 2012, AIDS.

[12]  Michael Rayment,et al.  Prevention of HIV-1 infection with early antiretroviral therapy , 2012, Journal of Family Planning and Reproductive Health Care.

[13]  E. Clementi,et al.  Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects. , 2012, The Journal of antimicrobial chemotherapy.

[14]  R. Tubiana,et al.  Raltegravir Concentrations in the Genital Tract of HIV-1-Infected Women Treated with a Raltegravir-Containing Regimen (DIVA 01 Study) , 2011, Antimicrobial Agents and Chemotherapy.

[15]  J. Hogan,et al.  Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load , 2010, AIDS.

[16]  Ning Wang,et al.  HIV Transmission Risk Among Serodiscordant Couples: A Retrospective Study of Former Plasma Donors in Henan, China , 2010, Journal of acquired immune deficiency syndromes.

[17]  Lenine J P Liebenberg,et al.  Persistence of Genital Tract T Cell Responses in HIV-Infected Women on Highly Active Antiretroviral Therapy , 2010, Journal of Virology.

[18]  J. Yamamoto-Furusho,et al.  High gene expression of MDR1 (ABCB1) is associated with medical treatment response and long-term remission in patients with ulcerative colitis. , 2010, Inflammatory bowel diseases.

[19]  G. Jansen,et al.  ABC drug transporters and immunity: novel therapeutic targets in autoimmunity and cancer , 2009, Journal of leukocyte biology.

[20]  B. Damle,et al.  Maraviroc Concentrates in the Cervicovaginal Fluid and Vaginal Tissue of HIV-Negative Women , 2009, Journal of acquired immune deficiency syndromes.

[21]  A. Kashuba,et al.  An accurate and precise high-performance liquid chromatography method for the rapid quantification of the novel HIV integrase inhibitor raltegravir in human blood plasma after solid phase extraction. , 2008, Analytica chimica acta.

[22]  Myron S. Cohen,et al.  Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis , 2007, AIDS.

[23]  C. Kovacs,et al.  Antiretroviral Activity, Pharmacokinetics, and Tolerability of MK-0518, a Novel Inhibitor of HIV-1 Integrase, Dosed As Monotherapy for 10 Days in Treatment-Naive HIV-1-Infected Individuals , 2006, Journal of acquired immune deficiency syndromes.

[24]  S. Cu-Uvin,et al.  Protease Inhibitor and Nonnucleoside Reverse Transcriptase Inhibitor Concentrations in the Genital Tract of HIV-1-Infected Women , 2004, Journal of acquired immune deficiency syndromes.

[25]  J. Baeten,et al.  Use of hormonal contraceptives and risk of HIV-1 transmission : a prospective cohort study , 2011 .

[26]  A. Kashuba,et al.  Quantifying the HIV-1 integrase inhibitor raltegravir in female genital tract secretions using high-performance liquid chromatography with ultraviolet detection. , 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[27]  S. Krähenbühl,et al.  Regulation of BCRP (ABCG2) and P-Glycoprotein (ABCB1) by Cytokines in a Model of the Human Blood–Brain Barrier , 2009, Cellular and Molecular Neurobiology.

[28]  E. Capparelli,et al.  Pharmacokinetics of Antiretrovirals in Pregnant Women , 2004, Clinical pharmacokinetics.